抗高脂单疗新用户的长期坚持和药物使用模式:开发风险预测模型
Xuechun Li1, Eelko Hak1, Jens H J Bos1
1Unit PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.
Journal of evaluation in clinical practice
|February 19, 2026
概括
西姆瓦斯塔丁使用者表现出对超脂血症管理的坚持和持续率最高. 高龄,女性性别和糖尿病药物使用与更好的坚持有关,为个性化心血管疾病预防策略提供了信息.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 长期坚持和药物模式对于管理高脂血症至关重要.
- 关于这些模式的现有证据仍然有限.
研究的目的:
- 评估抗超脂血症单一治疗的长期坚持和药物使用模式.
- 识别与药物守和使用相关的风险因素.
- 开发高脂血症治疗结果的风险预测模型.
主要方法:
- 使用IADB.nl发行数据库进行回顾性初始队列研究.
- 包括新使用特定抗高脂单一疗法 (simvastatin,pravastatin,fluvastatin,atorvastatin,rosuvastatin,纤维酸盐) 的新用户.
- 风险预测模型的后勤回归与大约10年的随访.
主要成果:
- 西姆瓦斯塔丁使用者表现出较高的坚持 (83.6%-90.2%) 和最高的持续率 (39.2%).
- 年龄较大 (≥40岁),女性性别和同时使用糖尿病药物与更好的坚持和持续相关.
- 男性患者的坚持率较低,但持续率较高;抗帕金森药物使用者的持续率较低.
结论:
- 与其他单一疗法相比,simvastatin表现出优异的坚持和延续.
- 老年患者,女性和服用糖尿病药物的患者从改善的坚持中受益.
- 结果支持个性化策略,以优化心血管疾病预防在高脂血症管理.
相关概念视频
01:26Atherosclerosis III: Management
465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
01:29Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
328
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
328
01:29Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
01:12Analysis of Population Pharmacokinetic Data
829
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
829